DrugPatentWatch Database Preview

KINEVAC Drug Profile

« Back to Dashboard

When do Kinevac patents expire, and when can generic versions of Kinevac launch?

Kinevac is a drug marketed by Bracco and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sincalide profile page.

Summary for KINEVAC

International Patents:	10
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	36
Clinical Trials:	1
Patent Applications:	329
Drug Prices:	Drug price information for KINEVAC
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KINEVAC
Prior Art and Litigation Support	Order Prior Art and Litigation support for KINEVAC
DailyMed Link:	KINEVAC at DailyMed

Generic Entry Opportunity Date for KINEVAC

NDA:

017697

Dosage:

INJECTABLE;INJECTION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for KINEVAC

Drug Class

Cholecystokinin Analog

Synonyms for KINEVAC

(Tyr[SO3H]27)Cholecystokinin fragment 26-33 Amide

[125I]CCK-8

1-De(5-oxo-L-proline)-2-de-L-glutamine-5-L-methioninecaerulein

126S323

25126-32-3

25345-10-2

89911-55-7

9038-72-6

91921-74-3

A817659

AC1L1OGF

AKOS015896031

AKOS016340423

Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

Asp-Tyr[SO3 H]-Met-Gly-Trp-Met -Asp-Phe-NH2

Asp-Tyr[SO3 H]-Met-Gly-Trp-Met-Asp-Phe-NH2

Asp26-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-PheNH2

BDBM21147

C49H62N10O16S3

Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-5-L-methionine-

CAS-25126-32-3

CCK 26-33, sulfated

CCK C-terminal octapeptide

CCK-8

CCK-8 (sulphated)

CCK-8, sulfated

CCK-8(SO3)

CHEBI:135946

CHEMBL1121

cholecystokinin 8

cholecystokinin C-terminal octapeptide

cholecystokinin fragment 26-33 amide (sulphated)

Cholecystokinin octapeptide

Cholecystokinin Octapeptide, sulfated

Cholecystokinin-pancreozymin

CS-042

CS-5963

D05845

DB09142

DSSTox_CID_28543

DSSTox_GSID_48617

DSSTox_RID_82815

DTXSID7048617

EINECS 246-639-0

FT-0630515

GTPL864

H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

HS-2026

Human CCK-8

HY-P0093

I06-1840

IZTQOLKUZKXIRV-YRVFCXMDSA-N

Kinevac (TN)

L-alpha-Aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide

L-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide hydrogen sulfate (ester)

LS-53094

M03GIQ7Z6P

MFCD00079849

MolPort-006-124-517

NCGC00167273-01

NCGC00183278-01

NCGC00183363-01

O411

Pancreozymin

Pancreozymin C-terminal octapeptide

SC-47569

SCHEMBL122365

SCHEMBL1425223

Sincalida

Sincalida [INN-Spanish]

Sincalide

Sincalide (Kinevac)

Sincalide (USP/INN)

Sincalide [USAN:BAN:INN]

Sincalide [USAN:USP:INN:BAN]

Sincalidum

Sincalidum [INN-Latin]

SQ 19844

SQ-19844

Syncalide

Tox21_112955

Tox21_113481

UNII-M03GIQ7Z6P

US Patents and Regulatory Information for KINEVAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	KINEVAC	sincalide	INJECTABLE;INJECTION	017697-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes			Y

Expired US Patents for KINEVAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	KINEVAC	sincalide	INJECTABLE;INJECTION	017697-001	Approved Prior to Jan 1, 1982

International Patents for KINEVAC

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2005027954
Austria	502647
Japan	2006515321
Canada	2503982
China	100374154
Japan	4751993
China	1756557